Puromycin DiHCl Solution (10 mg/mL in 20 mM HEPES)

- Overview
  - Puromycin Dihydrochloride (DiHCl) solution is an aminonucleoside antibiotic solution derived from Streptomyces alboniger. Puromycin DiHCl is routinely used as a selective agent in transfection and transformation protocols.
    Puromycin DiHCl solution is prepared at 10 mg/mL in 20 mM HEPES buffer.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    During translation, Puromycin enters the ribosomal “A” site and disrupts peptide transfer. As a result, the ribosome stops and the peptide chain is terminated leading to a nonfunctional protein.
- Properties
  - CAS Number
    
    58-58-2
    
    Molecular Formula
    
    C22H29N7O5•2HCl
    
    Molecular Weight
    
    544.43
    
    Appearance
    
    Clear and colorless or light yellow solution
    
    Other Properties
    
    Source: Streptomyces alboniger
    PH: 6.2 - 6.8
    Purity Level: (Powder) >98%
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Puromycin Dihydrochloride is active against both prokaryotic and eurkaryotic cells.
    
    Eukaryotic Cell Culture Applications: Puromycin Dihydrochloride is commonly used as a selective agent to isolate mammalian cells after transfection with the pac gene. The pac gene encodes puromycin N-acetyltransferase; a protein that inactivates Puromycin by acetylation.
    Conti et al. used Puromycin DiHCl solution (TOKU-E) to select for eGFP expressing A549 cells. Polymeric nanocarriers and their oral inhalation formulations for the regional delivery of nucleic acids to the lungs.
    Sandoval-Jaime et al. used Puromycin DiHCl (TOKU-E) to select for stably transfected cells. Recovery of murine norovirus and feline calicivirus from plasmids encoding EMCV IRES in stable cell lines expressing T7 polymerase.
    Mutonga et al. used Puromycin (TOKU-E) to select for resistant cells transformed with a vector containing SUV39H2 (a histone methyltransferase) and a puromycin resistance gene. Targeting suppressor of variegation 3-9 homologue 2 (SUV39H2) in acute lymphoblastic leukemia (ALL)."
    Foltyn et al. used Puromycin, G418 Disulfate and Hygromycin B (TOKU-E): The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.
    For more information on relevant cell lines, media, and working concentrations, please visit the TOKU-E Cell Culture Database.